Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1301 for NY-ESO-1-positive synovial sarcoma
jRCT2073250089Recruiting
- Sponsor
- Takara Bio Inc.
- Start
- Nov 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-NY-ESO-1 TCR-T in synovial sarcoma (SS), sponsored by Takara Bio Inc. Primary endpoint: Overall response rate. Started Nov 2025; status: recruiting.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on jRCT2073250089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073250089.